Google DeepMind’s Deeptminy Deeplement laboratories collect 600 million dollars

Digest opened free editor

Rola Khaleda, FT editor, chooses her favorite stories in this weekly newsletter.

Isomorphic Labs, Discovery Starts, which comes out of the Google artificial intelligence unit, has collected $ 600 million in the first foreign financing round, where investors are betting on the possibility of “disease solution”.

The London -based group donation collection, which is the CEO, Sir Dimis Hasabis, the Nobel Prize winner, the New York -based investor who is also among the largest supporters of Chatgpt Openai.

The tour, announced on Monday, joined the GV, Arm Capital Arm of Alphabet, the parent company of Google. It also included more investment from the alphabet.

Additional financial details have not been revealed, such as Isomorphic Labs evaluation and the new property structure. However, the majority alphabet is still the majority.

The collection of donations is among the largest companies even for AI in the United Kingdom, as it provides a financial payment Al -Hasabi Pay to the medications designed by artificial intelligence in clinical trials by the end of the year.

He said: “This funding will increase the development of the drug design engine of artificial intelligence from the following intelligence, and helps us to enhance our programs in clinical development, which is an important step forward towards our mission of solving all diseases with the help of artificial intelligence.”

The company said that the investment will help accelerate artificial intelligence and development research in the design of medicines and will allow the company to expand its team.

“We believe that ISOMORPHIC has obtained a rare site to determine a new era for the discovery and design of drugs, and we are deeply inspired by their mission and the exceptional progress they have made so far,” said Josh Kushner, founder and CEO of Thrive Capital.

The similar laboratories were removed from Deepmind In 2021, since then, a partnership has been made with large pharmaceutical companies, such as Novartis and Eli Lilly, which is keen to reduce costs and develop medicines faster.

Last May, DeepMind revealed Alphafold 3, an Amnesty International model that can predict the structures of DNA and RNA genetic code, as well as links, which are particles related to others that can be important signs of the disease. Isomorphic LABS researchers use the tool as well as the royal artificial intelligence models to operate predictions and simulate drug development.

In the first year of the full operations of the company in 2023, The losses were reported From 60 million pounds, up from 17 million pounds in the previous year, according to its latest accounts in Companies House. Isomorphic Labs also stated that it has grown the costs of research and development to 49 million pounds from 12 million pounds, and the costs of its employees have doubled three times to 20 million pounds with the number of employees 71.

“I have long felt that improving human health is the most important thing we can do with artificial intelligence and today it represents a big step towards a new era of drugs,” said Hassabis, who jointly received the Nobel Prize for Chemistry last October to develop alphafold, an Amnesty International tool that could predict the structure of proteins.